Skip to main content
. 2022 Mar 1;5(3):e220587. doi: 10.1001/jamanetworkopen.2022.0587

Figure 2. Association Between Epstein-Barr Virus (EBV) DNA Titer and an Ultimate Outcome of Durable Clinical Benefit (DCB).

Figure 2.

A, DCB rate for patients with different baseline EBV DNA titers (left), a ratio of the EBV DNA titer at week 4 to that at baseline (W4 to baseline ratio) (middle), and the trend of EBV DNA titer during the first 8 weeks (right). B, W4 to baseline ratio of EBV DNA titer and the outcome of DCB or no durable benefit (NDB). The black horizontal line at 1.0 and the blue horizontal dotted line at 0.50 indicate a W4 to baseline ratio of 0.50 and 1.0. C, W4 to baseline ratio of EBV DNA titer in the DCB group and NDB group. The dots indicate the ratio. To clearly show the results, we omitted 5 outliers (7.4, 11.2, 12.8, 13.5, and 21.8 in the NDB group). D, Patients with an increasing trend (left) or decreasing trend (right) of EBV DNA titer during the first 8 weeks and their ultimate outcomes (DCB or NDB). The cutoff value for the baseline EBV DNA titer was 10 000 IU/mL. Durable clinical benefit was defined as progression-free survival of at least 6 months. No durable benefit was defined as progression of disease or stable disease that lasted 6 months or less. The fold decrease was defined as the W4 to baseline ratio. A decreasing trend was defined as no increase in EBV DNA titer during the first 8 weeks of therapy; if patients did not meet this requirement, they were said to have an increasing trend.